Ministry of Health and Welfare Holds 4th Pharmaceutical Industry Innovation Public-Private Consultative Body
Discusses Strengthening Links from Drug Development to Commercialization

The government and pharmaceutical industry are exploring public-private cooperation measures to promote the commercialization of domestically developed new drugs and their entry into global markets, including through global clinical trials, regulatory approval and manufacturing, and overseas marketing.


New Drug Candidate Share Ranks Third Globally... "Need to Build Global Clinical Trial and Marketing Capabilities" View original image

The Ministry of Health and Welfare said it held the 4th Pharmaceutical Industry Innovation Public-Private Consultative Body at Sangyeonjae Seoul Station in Jung-gu, Seoul, on November 18. Attended by industry representatives, experts, and officials from the government and public institutions, the meeting reviewed the development of domestic biopharmaceuticals, improved drugs, and natural product medicines, and discussed ways to promote new drug development going forward.


Since Sunpla, the country's first new drug, an anticancer treatment, was approved in 1999, a total of 45 new drugs have been developed and approved over the past 27 years. South Korea's share of new drug candidates has reached 6%, ranking third globally after the United States and China. Since the system was introduced in 2008, 172 improved drugs have also been approved, contributing to the management of chronic diseases in South Korea.


However, key challenges have included the difficulties domestic pharmaceutical companies face in conducting global Phase 3 clinical trials, obtaining drug approvals and manufacturing products, and carrying out global marketing, all of which require substantial capital. Another concern is that inadequate connections among new drug development infrastructure make it difficult for candidate substances to advance to commercialization.


At the meeting, Jeon Bokhwan, a director at the Korea Drug Development Fund, presented on domestic new drug development trends and future prospects, as well as the strategies of major global pharmaceutical companies, under the theme "Status and Outlook for Domestically Developed New Drugs." He also introduced ways to accelerate new drug development using artificial intelligence (AI) and efficiently connect the resources needed throughout the development process.


Shin Haegon, an executive at Hanmi Pharmaceutical, shared experiences and success factors from actual overseas expansion in a presentation titled "Success Stories in the Global Expansion of Improved Drugs and New Drugs." Based on the outcome of the second working-level consultative meeting held on November 4, participants also discussed measures to manage contract sales organizations (CSOs), scale up and specialize companies focused on generic drugs, and help companies become exporters.


"South Korea's new drug sector has grown to rank third globally in its share of new drug candidates and has made significant quantitative and qualitative progress. However, it is also true that we still fall short in global Phase 3 clinical trials and global marketing, areas led by major pharmaceutical companies worldwide," said Jeong Gyeongsil, director general of the Health and Medical Policy Office at the Ministry of Health and Welfare. "We will work to help domestic pharmaceutical companies commercialize domestically developed new drugs and enter global markets effectively."


"Developing new drugs and improved drugs is an important area for domestic pharmaceutical companies seeking to grow into global big pharma," said Noh Yeonhong, chairman of the Korea Pharmaceutical and Bio-Pharma Manufacturers Association. "The industry will strengthen research and development investment and global marketing to improve its capabilities, and the association will work closely with the government to ensure that domestically developed new drugs can be developed and commercialized effectively."



The Ministry of Health and Welfare plans to draw up measures to promote domestic new drug development based on the views presented at the meeting.


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing